Liver Transplantation After Combination Therapy Based on Immune Checkpoint Inhibitors: A Multicenter Retrospective Study of Safety and Efficacy
Organ Medicine · 2026-03 · 3 (1) · 12-19
DOI: 10.1002/orm2.70034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Organ Medicine, online erschienen am 28.02.2026. Verfasst von Huanquan Chen und 7 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Background
Perioperative use of immune checkpoint inhibitors (ICIs) in patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT) remains controversial, primarily because of concerns regarding allograft rejection. The present study evaluated the safety and potential efficacy of ICIs as a downstaging or bridging therapy prior to LT.
Methods
This multicenter retrospective analysis included 17 patients with HCC from six Chinese centers who received at least one cycle of preoperative ICI therapy followed by LT.
Results
The cohort had a mean age of 51.1 ± 9.9 years; 94.1% were men. Disease stages were Barcelona Clinic Liver Cancer Stage A ( n = 2), B ( n = 10), and C ( n = 5). All patients received multimodal therapy combining ICIs (sintilimab, n = 13; tislelizumab, n = 2; atezolizumab, n = 1; and pembrolizumab, n = 1) with locoregional and/or systemic treatments. In accordance with the Response Evaluation Criteria in Solid Tumors 1.1 criteria, the objective response rate was 76.5% (13/17), comprising 1 complete response and 12 partial responses. Following LT, all patients received a tacrolimus‐based immunosuppressive regimen. Over a median follow‐up of 11.4 months, no indications of graft rejection and no tumor recurrence were observed.
Conclusion
In the study cohort, preoperative ICI‐based therapy was not associated with an increased risk of rejection, suggesting its short‐term safety in the context of LT for HCC. Larger prospective studies are warranted to validate these findings and to further define the efficacy and safety profile of this approach.
Förderung
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Chen, H., Dai, T., Gao, J., Li, C., Chen, H., Deng, F., Ma, N., & Wang, G. (2026). Liver Transplantation After Combination Therapy Based on Immune Checkpoint Inhibitors: A Multicenter Retrospective Study of Safety and Efficacy. Organ Medicine, 3(1), 12-19. https://doi.org/10.1002/orm2.70034
Vancouver
Chen H, Dai T, Gao J, Li C, Chen H, Deng F, et al. Liver Transplantation After Combination Therapy Based on Immune Checkpoint Inhibitors: A Multicenter Retrospective Study of Safety and Efficacy. Organ Medicine. 2026;3(1):12-19. doi:10.1002/orm2.70034
BibTeX
@article{Chen2026,
author = {Chen, Huanquan and Dai, Tianxing and Gao, Jie and Li, Chuanjiang and Chen, Huanwei and Deng, Feiwen and Ma, Nan and Wang, Guoying},
title = {Liver Transplantation After Combination Therapy Based on Immune Checkpoint Inhibitors: A Multicenter Retrospective Study of Safety and Efficacy},
journal = {Organ Medicine},
year = {2026},
volume = {3},
number = {1},
pages = {12--19},
doi = {10.1002/orm2.70034}
}
EUVIMED